Dauricine Inhibits Non-small Cell Lung Cancer Development by Regulating PTEN/AKT/mTOR and Ras/MEK1/2/ERK1/2 Pathways in a FLT4-dependent Manner

Overview

Journal Curr Cancer Drug Targets

Publisher Bentham Science Publishers

Specialty Oncology

Date 2024 Feb 7

PMID 38321898

Authors

Jinna Liang

Panpan Lei

Xinyue Su

Jiapan Gao

Bingxi Ren

Yuxiu Zhang

Xiaoyu Ma

Weina Ma

Affiliations

Soon will be listed here.

Abstract

Objective: Non-small cell lung cancer (NSCLC) is still a solid tumor with high malignancy and poor prognosis. Vascular endothelial growth factor receptor 3 (FLT4, VEGFR3) is overexpressed in NSCLC cells, making it a potential target for NSCLC treatment. In this study, we aimed to explore the anti-cancer effects of dauricine on NSCLC cells and its mechanism targeting FLT4.

Methods: We found that dauricine inhibited the growth of NCI-H1299 cells by blocking the cycle in the G2/M phase through flow cytometry analysis. In addition, dauricine also inhibited the migration of NCI-H1299 cells by wound healing assay and transwell migration assay. More importantly, our empirical analysis found the anti-cancer effect of dauricine on NCI-H1299 cells and the protein level of FLT4 had a distinctly positive correlation, and this effect was weakened after FLT4 knockdown.

Results: It is suggested that dauricine suppressed the growth and migration of NCI-H1299 cells by targeting FLT4. Furthermore, dauricine inhibited FLT4 downstream pathways, such as PTEN/AKT/mTOR and Ras/MEK1/2/ERK1/2, thereby regulating cell migration-related molecule MMP3 and cell cycle-related molecules (CDK1, pCDK1-T161, and cyclin B1).

Conclusion: Dauricine may be a promising FLT4 inhibitor for the treatment of NSCLC.

References

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Molina J, Yang P, Cassivi S, Schild S, Adjei A . Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008; 83(5):584-94. PMC: 2718421. DOI: 10.4065/83.5.584. View

Wang J, Zhang R, Lin Z, Zhang S, Chen Y, Tang J . CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer. J Hematol Oncol. 2020; 13(1):99. PMC: 7370470. DOI: 10.1186/s13045-020-00926-x. View

Wang M, Herbst R, Boshoff C . Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021; 27(8):1345-1356. DOI: 10.1038/s41591-021-01450-2. View

Ellis L, Hicklin D . VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008; 8(8):579-91. DOI: 10.1038/nrc2403. View

Yeh Y, Cheng C, Yang S, Tseng C, Chang T, Tsai S . Targeting the VEGF-C/VEGFR3 axis suppresses Slug-mediated cancer metastasis and stemness via inhibition of KRAS/YAP1 signaling. Oncotarget. 2016; 8(3):5603-5618. PMC: 5354933. DOI: 10.18632/oncotarget.13629. View

Lim J, Ryu J, Kim E, Ham S, Kang D . Inhibition of Vascular Endothelial Growth Factor Receptor 3 Reduces Migration of Gastric Cancer Cells. Cancer Invest. 2015; 33(8):398-404. DOI: 10.3109/07357907.2015.1047509. View

Shigetomi S, Imanishi Y, Shibata K, Sakai N, Sakamoto K, Fujii R . VEGF-C/Flt-4 axis in tumor cells contributes to the progression of oral squamous cell carcinoma via upregulating VEGF-C itself and contactin-1 in an autocrine manner. Am J Cancer Res. 2018; 8(10):2046-2063. PMC: 6220132. View

Tacconi C, Ungaro F, Correale C, Arena V, Massimino L, Detmar M . Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer. Cancer Res. 2019; 79(16):4196-4210. DOI: 10.1158/0008-5472.CAN-18-3657. View

10.

Tuomela J, Valta M, Seppanen J, Tarkkonen K, Vaananen H, Harkonen P . Overexpression of vascular endothelial growth factor C increases growth and alters the metastatic pattern of orthotopic PC-3 prostate tumors. BMC Cancer. 2009; 9:362. PMC: 2767356. DOI: 10.1186/1471-2407-9-362. View

11.

Dias S, Choy M, Alitalo K, Rafii S . Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood. 2002; 99(6):2179-84. DOI: 10.1182/blood.v99.6.2179. View

12.

Sun P, Gao J, Liu Y, Wei L, Wu L, Liu Z . RNA interference (RNAi)-mediated vascular endothelial growth factor-C (VEGF-C) reduction interferes with lymphangiogenesis and enhances epirubicin sensitivity of breast cancer cells. Mol Cell Biochem. 2007; 308(1-2):161-8. DOI: 10.1007/s11010-007-9624-1. View

13.

Su J, Yen C, Chen P, Chuang S, Hong C, Kuo I . The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer. 2006; 96(4):541-5. PMC: 2360045. DOI: 10.1038/sj.bjc.6603487. View

14.

Li J, Zhang W, Xia H, Liu Y . [High expression of VEGFR3 is positively associated with poor prognosis in lung adenocarcinoma]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2019; 35(11):1023-1029. View

15.

Jiang L, Guo T, Jiang Y, Liu P, Bai Y . Dauricine inhibits human pancreatic carcinoma cell proliferation through regulating miRNAs. Mol Omics. 2021; 17(4):630-640. DOI: 10.1039/d1mo00156f. View

16.

Zhang S, Ren Y, Qiu J . Dauricine inhibits viability and induces cell cycle arrest and apoptosis via inhibiting the PI3K/Akt signaling pathway in renal cell carcinoma cells. Mol Med Rep. 2018; 17(5):7403-7408. DOI: 10.3892/mmr.2018.8732. View

17.

Collins I, Workman P . New approaches to molecular cancer therapeutics. Nat Chem Biol. 2006; 2(12):689-700. DOI: 10.1038/nchembio840. View

18.

Li Z, Mao L, Yu B, Liu H, Zhang Q, Bian Z . GB7 acetate, a alkaloid from , possesses anticancer effects in colorectal cancer cells. J Pharm Anal. 2022; 12(2):339-349. PMC: 9091789. DOI: 10.1016/j.jpha.2021.06.007. View

19.

Zhang Y, Fei H, Guo J, Zhang X, Wu S, Zhong L . Dauricine suppresses the growth of pancreatic cancer by modulating the Hedgehog signaling pathway. Oncol Lett. 2019; 18(5):4403-4414. PMC: 6781764. DOI: 10.3892/ol.2019.10790. View

20.

Yang Z, Li C, Wang X, Zhai C, Yi Z, Wang L . Dauricine induces apoptosis, inhibits proliferation and invasion through inhibiting NF-kappaB signaling pathway in colon cancer cells. J Cell Physiol. 2010; 225(1):266-75. DOI: 10.1002/jcp.22261. View